Anuradha Illendula

723 citations

19 papers · 435 indexed · h-index 10

Co-authors: John H. Bushweller Lucio H. Castilla John Anto Pulikkan Lihua Julie Zhu Roger A. Rajewski Adam BoultonYan GaoLiting Xue
Topics: Acute Myeloid Leukemia Research (9 papers)Ubiquitin and proteasome pathways (7 papers)Protein Degradation and Inhibitors (7 papers)
Cited by: Hematology Molecular Biology Genetics
Journals: Science Cell Proceedings of the National Academy of Sciences
Partner nations: United States Netherlands Germany

In The Last Decade

Anuradha Illendula

17 papers receiving 435 citations

Peers

Countries citing papers authored by Anuradha Illendula

Since Specialization

Citations

This map shows the geographic impact of Anuradha Illendula's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anuradha Illendula with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anuradha Illendula more than expected).

Fields of papers citing papers by Anuradha Illendula

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Anuradha Illendula. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anuradha Illendula. The network helps show where Anuradha Illendula may publish in the future.

Co-authorship network of co-authors of Anuradha Illendula

This figure shows the co-authorship network connecting the top 25 collaborators of Anuradha Illendula. A scholar is included among the top collaborators of Anuradha Illendula based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Anuradha Illendula. Anuradha Illendula is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

#	Work	Indexed citations
1	Nanoromidepsin, a polymer nanoparticle of the HDAC inhibitor, improves safety and efficacy in models of T-cell lymphoma 2025 ·Blood ·Ipsita Pal,Anuradha Illendula,(unknown),John S. Manavalan,(unknown),(unknown),(unknown),(unknown),Enrica Marchi,Todd E. Fox,(unknown),Kallesh D. Jayappa,Jihane Khalife,Jeffrey W. Craig,Thomas P. Loughran,David J. Feith,Owen A. O’Connor	0
2	Synthesis and Preclinical Development of a Promising Novel Romidepsin Nanoparticle for the Treatment of Peripheral T‐Cell Lymphoma (PTCL) 2023 ·Hematological Oncology ·Owen A. O’Connor,Anuradha Illendula,Kallesh D. Jayappa,Todd E. Fox,Thomas P. Loughran,David J. Feith,Enrica Marchi,Ipsita Pal	1
3	NOXA expression drives synthetic lethality to RUNX1 inhibition in pancreatic cancer 2022 ·Proceedings of the National Academy of Sciences ·(unknown),Stefanos A. Bamopoulos,(unknown),(unknown),Chuanbing Zang,(unknown),Alexander T. den Dekker,Rutger W. W. Brouwer,Apoorva Baluapuri,Stefan Habringer,(unknown),Anuradha Illendula,Oliver H. Krämer,Markus Schick,Elmar Wolf,Wilfred F. J. van IJcken,Iréne Esposito,Ulrich Keller,Günter Schneider,Matthias Wirth	22
4	Nanoliposome C6‐Ceramide in combination with anti‐CTLA4 antibody improves anti‐tumor immunity in hepatocellular cancer 2022 ·The FASEB Journal ·Xiaoqiang Qi,Feng Wu,Sung Hoon Kim,Jussuf T. Kaifi,Eric T. Kimchi,(unknown),Anuradha Illendula,Todd E. Fox,Mark Kester,Kevin F. Staveley-O’Carroll,Guangfu Li	13
5	A nano-enhanced vaccine for metastatic melanoma immunotherapy 2022 ·Cancer Drug Resistance ·(unknown),Walter C. Olson,(unknown),Anuradha Illendula,(unknown),(unknown),Todd E. Fox,Susan J. Walker,(unknown),Craig L. Slingluff,Mark Kester,(unknown)	6
6	Regulome analysis in B-acute lymphoblastic leukemia exposes Core Binding Factor addiction as a therapeutic vulnerability 2022 ·Nature Communications ·Jason Wray,Elitza Deltcheva,Charlotta Böiers,Simon Richardson,(unknown),John Brown,Sladjana Gagrica,Yanping Guo,Anuradha Illendula,Joost H.A. Martens,Hendrik G. Stunnenberg,John H. Bushweller,Rachael Nimmo,Tariq Enver	6
7	Nanoliposomal C6-Ceramide Exhibits Synergistic Anti-Cancer Activity with a Small Molecule Agonist of PP2A in Chronic Lymphocytic Leukemia 2022 ·Blood ·Kallesh D. Jayappa,(unknown),Caroline Farrington,Anuradha Illendula,Susan J. Walker,Michael E. Williams,Craig A. Portell,(unknown),(unknown),Mark Kester	1
8	Inhibition of the RUNX1-CBFβ transcription factor complex compromises mammary epithelial cell identity: a phenotype potentially stabilized by mitotic gene bookmarking 2020 ·Oncotarget ·(unknown),(unknown),Joseph R. Boyd,Jonathan A. R. Gordon,Nicole A. Bouffard,Andrew J. Fritz,Anuradha Illendula,John H. Bushweller,Jane B. Lian,Janet L. Stein,Sayyed K. Zaidi,Gary S. Stein	11
9	RUNX1-targeted therapy for AML expressing somatic or germline mutation in RUNX1 2019 ·Blood ·Christopher P. Mill,Warren Fiskus,Courtney D. DiNardo,Yimin Qian,Kanak Raina,Kimal Rajapakshe,Dimuthu Perera,Cristian Coarfa,Tapan M. Kadia,Joseph D. Khoury,Dyana T. Saenz,(unknown),Anuradha Illendula,Koichi Takahashi,Steven M. Kornblau,Michael R. Green,P. Andrew Futreal,John H. Bushweller,Craig M. Crews,Kapil N. Bhalla	77
10	RUNX proteins desensitize multiple myeloma to lenalidomide via protecting IKZFs from degradation 2019 ·Leukemia ·(unknown),Álvaro Gutiérrez-Uzquiza,(unknown),Renxu Chang,Dan T. Vogl,Alfred L. Garfall,(unknown),Anita Saraf,Laurence Florens,Michael P. Washburn,Anuradha Illendula,John H. Bushweller,Luca Busino	44
11	The interaction between RUNX2 and core binding factor beta as a potential therapeutic target in canine osteosarcoma 2019 ·Veterinary and Comparative Oncology ·Fernando Alegre,(unknown),(unknown),Anuradha Illendula,John H. Bushweller,Luke A. Wittenburg	6
12	Small molecule inhibition of the CBFβ/RUNX interaction decreases ovarian cancer growth and migration through alterations in genes related to epithelial-to-mesenchymal transition 2018 ·Gynecologic Oncology ·(unknown),Anuradha Illendula,Yan Gao,Danielle C. Llaneza,Adam Boulton,Anant Shah,Roger A. Rajewski,Charles N. Landen,David Wotton,John H. Bushweller	13
13	CBFβ-SMMHC Inhibition Triggers Apoptosis by Disrupting MYC Chromatin Dynamics in Acute Myeloid Leukemia 2018 ·Cell ·John Anto Pulikkan,Mahesh Hegde,(unknown),Houda Belaghzal,Anuradha Illendula,(unknown),(unknown),Jianhong Ou,Carsten Müller‐Tidow,Scot A. Wolfe,Lihua Julie Zhu,Job Dekker,John H. Bushweller,Lucio H. Castilla	69
14	RUNX1 is required for oncogenic Myb and Myc enhancer activity in T-cell acute lymphoblastic leukemia 2017 ·Blood ·(unknown),Anuradha Illendula,John Anto Pulikkan,Justine E. Roderick,(unknown),Jun Yu,Nicole Hermance,Lihua Julie Zhu,Lucio H. Castilla,John H. Bushweller,Michelle A. Kelliher	65
15	A tool compound targeting the core binding factor Runt domain to disrupt binding to CBFβ in leukemic cells 2017 ·Leukemia & lymphoma ·(unknown),Anuradha Illendula,Jolanta Grembecka,Charles Schmidt,Yunpeng Zhou,Virginie Esain,Wanda Kwan,Isaura M. Frost,Trista E. North,Roger A. Rajewski,Nancy A. Speck,John H. Bushweller	9
16	A small-molecule inhibitor of the aberrant transcription factor CBFβ-SMMHC delays leukemia in mice 2015 ·Science ·Anuradha Illendula,John Anto Pulikkan,Hongliang Zong,Jolanta Grembecka,Liting Xue,Siddhartha Sen,Yunpeng Zhou,Adam Boulton,Aravinda Kuntimaddi,Yan Gao,Roger A. Rajewski,Mónica L. Guzmán,Lucio H. Castilla,John H. Bushweller	89
17	Selective Inhibition of the Leukemia Fusion Protein CBFβ-SMMHC By Small Molecule AI-10-49 in the Treatment of Inv(16) AML 2014 ·Blood ·John Anto Pulikkan,Anuradha Illendula,Jolanta Grembecka,Liting Xue,Roger A. Rajewski,Mónica L. Guzmán,John H. Bushweller,Lucio H. Castilla	1
18	A Small Molecule Inhibitor of the CBFβ-SMMHC/RUNX Interaction Attenuates Inv(16) Leukemia in Vivo 2012 ·Blood ·John H. Bushweller,Anuradha Illendula,John Anto Pulikkan,Jolanta Grembecka,(unknown),Yunpeng Zhou,Liting Xue,Gao Yan,Lucio H. Castilla	2
19	Development of Small Molecule Inhibitors of the AML1-ETO and CBFβ-SMMHC Oncoproteins. 2007 ·Blood ·Jolanta Grembecka,(unknown),Yali Kong,Michael G. Douvas,Tomasz Cierpicki,Anuradha Illendula,Gwen Baber,(unknown),Liya Roudaia,Nancy A. Speck,Milton L. Brown,John H. Bushweller	0

About Anuradha Illendula

Anuradha Illendula is a scholar working on Hematology, Immunology and Molecular Biology, having authored 19 papers that have together received 435 indexed citations. Recurring topics across this work include Acute Myeloid Leukemia Research (9 papers), Ubiquitin and proteasome pathways (7 papers) and Protein Degradation and Inhibitors (7 papers). The work is most often cited by research in Hematology (191 citations), Molecular Biology (317 citations) and Genetics (35 citations). Anuradha Illendula has collaborated with scholars based in United States, Netherlands and Germany. Frequent co-authors include John H. Bushweller, Lucio H. Castilla, John Anto Pulikkan, Lihua Julie Zhu, Roger A. Rajewski, Adam Boulton, Yan Gao, Liting Xue, Jolanta Grembecka and Yunpeng Zhou. Their work appears in journals such as Science, Cell and Proceedings of the National Academy of Sciences.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact